NCT00944905View on ClinicalTrials.gov

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Renal Cell CarcinomaNon-hodgkin's Lymphoma
Interventions
BIOLOGICAL

MDX-1203

Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.

Trial Locations (5)

21201

University of Maryland Greenebaum Cancer Center, Baltimore

30322

Emory University Winship Cancer Center, Atlanta

48109

The University of Michigan Health System, Ann Arbor

60637

The University of Chicago, Chicago

06520

Yale University School of Medicine, New Haven

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00944905 - Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | Biotech Hunter | Biotech Hunter